Assignee
ENLIVEN INC
US·4 granted patents·5 pending applications·283 citations·filing 1998–2025
Top patents by PatentIndex Score
9 records- 0190US11807638B25- and 6-azaindole compounds for inhibition of Bcr-Abl tyrosine kinasesENLIVEN INC·Filed 2022·Granted Nov 7, 2023·1 cites·44 claims
- 0285US11767321B25- and 6-azaindole compounds for inhibition of BCR-ABL tyrosine kinasesENLIVEN INC·Filed 2021·Granted Sep 26, 2023·1 cites·31 claims
- 0381US12240846B25- and 6-azaindole compounds for inhibition of Bcr-Abl tyrosine kinasesENLIVEN INC·Filed 2023·Granted Mar 4, 2025·0 cites·14 claims
- 0478US6393407B1Tracking user micro-interactions with web page advertisingENLIVEN INC·Filed 1998·Granted May 21, 2002·281 cites·1 claims
- 0573US2025236621A15- and 6-azaindole compounds for inhibition of bcr-abl tyrosine kinasesENLIVEN INC·Filed 2025·Application pending·0 cites
- 0666US2024228486A1Sulfone- and sulfoximine-based selective parp1 inhibitorsENLIVEN INC·Filed 2023·Application pending·0 cites
- 0764US2026078135A1Polycyclic quinazolines for inhibition of erbb2ENLIVEN INC·Filed 2023·Application pending·0 cites
- 0859US2024287062A1Naphthyridone compounds for inhibition of raf kinases and/or bcr-abl tyrosine kinasesENLIVEN INC·Filed 2022·Application pending·0 cites
- 0957US2025136595A1Acylated heterocyclic quinazoline derivatives as inhibitors of erbb2ENLIVEN INC·Filed 2022·Application pending·0 cites
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →